Novavax Inc vs Seagate Technology Holdings PLC — how do they compare? Novavax Inc trades at $9.88 (market cap $1.68B), while Seagate Technology Holdings PLC trades at $886.43 (market cap $205.65B). The key difference: Seagate Technology Holdings PLC is far larger — about 122.4× Novavax Inc's market cap, and Seagate Technology Holdings PLC pays a 0.33% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | STX | |
|---|---|---|
Market Cap | $1.68B | $205.65B |
Sector | Health | Technology |
52-Week High | $11.19 | $1.09K |
52-Week Low | $6.22 | $193.04 |
Enterprise Value | $1.26B | $207.80B |
Dividend Yield | — | 0.33% |
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, showing modest daily movement with a -0.29% decline. The stock maintains a bullish technical signal with strong moving average support. Recent quarterly earnings have consistently beaten expectations, though the company faces profitability challenges with a -59.87% net income margin. Positive developments include regulatory approvals for its updated COVID-19 vaccine and progress in the Sanofi partnership, driving investor optimism.
The outlook remains mixed with strong analyst support (74% buy ratings) but significant financial risks. Investment opportunity lies in the company's partnership strategy and Matrix-M adjuvant platform, while risks include cash flow challenges and competitive vaccine market pressures. The stock's low P/E ratio of 3.14 suggests potential undervaluation if operational improvements continue.
Seagate Technology (STX) trades at $904.38, up 6.49% today, with strong momentum driven by AI infrastructure demand. The stock shows bullish technical signals with support at $868 and resistance at $933. Recent earnings beats and robust 2026 revenue guidance of $12.2B highlight fundamental strength, though valuation ratios remain elevated with P/E at 65.06. Analyst consensus is bullish with a $1,130 price target, supported by institutional accumulation and positive media coverage of HAMR technology adoption.
Outlook: STX benefits from AI-driven storage demand and operational execution, but faces risks from high debt and competitive pressures. The stock's premium valuation requires sustained growth to justify upside. Near-term catalysts include Q3 earnings and product ramps, while macroeconomic volatility and execution missteps pose headwinds. Investor sentiment remains positive, but caution is warranted given rich multiples.
Trailing returns across standard periods
Latest headlines on both assets
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital
Read more on STX →